Dr. Kaufman, M.D. has been an academic leader in biomedicine for 35 years, serving as Chief of Hematology / Oncology, Vice Dean, and Vice Chancellor at Duke University, where he is an emeritus professor of Medicine and Biochemistry. After leaving Duke in 2002, he became President and CEO of The Wistar Institute in Philadelphia, from which he retired in March 2015 and is president emeritus. He now is Executive-in Residence for Pappas-Capital in North Carolina and founder of Kaufman LifeSciences.
In addition to his administrative leadership positions, Dr. Kaufman maintained an active research program investigating the genetics of blood diseases and cancer over his career. While at Duke, he had a medical practice in internal medicine and hematology/oncology, and was director of the hemoglobin and protein clinical laboratory as well as developer of the molecular diagnostic laboratory.
Dr. Kaufman has been a pace-setter for the growing life sciences industry in the greater Philadelphia region, having served on the board of directors for the Greater Philadelphia Chamber of Commerce; Select Greater Philadelphia’s CEO Council for Growth; the Greater Philadelphia Life Sciences Congress; the University City Science Center; BioAdvance – Biotechnology Greenhouse Corporation of Southeastern Pennsylvania; The University of the Sciences; and Osage Ventures II before joining Pappas-Capital.
With long-standing interests in both basic and applied cancer research, Dr. Kaufman has held leadership positions in national academic organizations in internal medicine and on committees within the National Institutes of Health, the National Academy of Sciences, and the American Association of Medical Colleges. A fellow of the American College of Physicians, he has received honors and awards for his work from the March of Dimes, the Leukemia and Lymphoma Society of America, the Arthritis Foundation, and others. The American Cancer Society awarded Dr. Kaufman with the 2008 Southeast Region Cancer Control Award, in recognition of his exemplary individual achievements in the field of cancer control. Dr. Kaufman was also named one of the first Searle Scholars, a prestigious program that supports top-flight academic research in biomedicine and chemistry.
He earned a Bachelor’s degree in Zoology and Biochemistry from the Ohio State University, and earned his medical degree from the Ohio State University College of Medicine.
Tony Ford-Hutchinson has more than 30 years of experience in pharmaceuticals, drug and vaccines discovery, research and development, business development, emerging markets and scientific strategy from his time working with Merck in increasing roles of global responsibility in R&D. Prior to being recruited to Merck, he worked at King’s College Hospital Medical School, in London, for nearly 10 years in the field of inflammation and arachidonic acid metabolism where he made some fundamental discoveries on leukotrienes, work that was put into practice at Merck Frosst, Canada, which eventually leading to Singulair® (leukotriene D4 receptor antagonist) and the Cox-2 inhibitors (Vioxx® and Arcoxia®). Subsequent career highlights at Merck relating to infectious disease include the development of HIV integrase inhibitor Isentress® and development & licensing of therapies to tackle drug-resistant bacterial infections. Tony’s most recent responsibility at Merck as head of Vaccine R&D led to commercialization of 4 vaccines; Gardasil®, Zostavax®, Proquad® and Rotateq®. After retiring from Merck Tony has been either an Independent Board Member, Scientific Advisory Board member or Chief Scientific Officer for a number of biotechs and non-profit organizations.